Trial reportThe Journal of infectious diseases2014
Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
Trial report in The Journal of infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Comparative Genomics of Clostridioides difficile.Advances in experimental medicine and biology · 2024Article
- Genomic epidemiology and transmission dynamics of recurrent Clostridioides difficile infection in Western Australia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Article
- Fidaxomicin for the Treatment ofAntibiotics (Basel, Switzerland) · 2022Review
- High Prevalence of Genetically RelatedFrontiers in microbiology · 2020Article
- Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment forOpen forum infectious diseases · 2019Article
- Genomics of the Pathogenic Clostridia.Microbiology spectrum · 2019Review
- Development and Implementation of Whole Genome Sequencing-Based Typing Schemes forFrontiers in public health · 2019Review
- Recent Progress for the Effective Prevention and Treatment of RecurrentInfectious diseases · 2018Article
- Coinfection and Emergence of Rifamycin Resistance during a Recurrent Clostridium difficile Infection.Journal of clinical microbiology · 2016Article
- Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-γ and expanding CD4(+)Foxp3(+) T cells in concordant heart transplantation.Laboratory investigation; a journal of technical methods and pathology · 2016Article
- Clostridium difficile Infection.Microbiology spectrum · 2016Review
- Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
- Utility of Whole-Genome Sequencing in Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks.Journal of clinical microbiology · 2016Article
- Within-host evolution of bacterial pathogens.Nature reviews. Microbiology · 2016Review
- Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Cold Spring Harbor perspectives in medicine · 2016Review
- Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.The Journal of infectious diseases · 2015Article
- A Genomic Approach to Resolving Relapse versus Reinfection among Four Cases of Buruli Ulcer.PLoS neglected tropical diseases · 2015Article
- Diversity and Evolution in the Genome of Clostridium difficile.Clinical microbiology reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Whole-genome sequencing was used to determine whether the reductions in recurrence of Clostridium difficile infection observed with fidaxomicin in pivotal phase 3 trials occurred by preventing relapse of the same infection, by preventing reinfection with a new strain, or by preventing both outcomes. Paired isolates of C. difficile were available from 93 of 199 participants with recurrences (28 were treated with fidaxomicin, and 65 were treated with vancomycin). Given C. difficile evolutionary rates, paired samples ≤2 single-nucleotide variants (SNVs) apart were considered relapses, paired samples >10 SNVs apart were considered reinfection, and those 3-10 SNVs apart (or without whole-genome sequences) were considered indeterminate in a competing risks survival analysis. Fidaxomicin reduced the risk of both relapse (competing risks hazard ratio [HR], 0.40 [95% confidence interval {CI}, .25-.66]; P = .0003) and reinfection (competing risks HR, 0.33 [95% CI, 0.11-1.01]; P = .05).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.